Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Asset Utilization Ratio (2016 - 2025)

Historic Asset Utilization Ratio for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to 0.77.

  • Protalix BioTherapeutics' Asset Utilization Ratio rose 2897.33% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year increase of 2897.33%. This contributed to the annual value of 0.68 for FY2024, which is 2757.35% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Asset Utilization Ratio is 0.77, which was up 2897.33% from 0.81 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Asset Utilization Ratio high stood at 0.87 for Q2 2023, and its period low was 0.42 during Q2 2024.
  • For the 5-year period, Protalix BioTherapeutics' Asset Utilization Ratio averaged around 0.68, with its median value being 0.7 (2022).
  • Per our database at Business Quant, Protalix BioTherapeutics' Asset Utilization Ratio crashed by 5180.14% in 2024 and then soared by 9376.24% in 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Asset Utilization Ratio (Quarter) stood at 0.49 in 2021, then surged by 73.52% to 0.85 in 2022, then fell by 10.08% to 0.76 in 2023, then rose by 3.9% to 0.79 in 2024, then decreased by 2.76% to 0.77 in 2025.
  • Its Asset Utilization Ratio was 0.77 in Q3 2025, compared to 0.81 in Q2 2025 and 0.81 in Q1 2025.